Clinical Trial Update: Adjuvant Treatment With Serplulimab，Trastuzumab and SOX in the HER-2 Positive GC/GEJC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating adjuvant therapy with serplulimab, trastuzumab, and the SOX regimen (S-1 plus oxaliplatin) for HER2-positive gastric …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Gastroesophageal Junction Cancer

Drugs mentioned

• OXALIPLATIN (Oxaliplatin)
• S-1 (tegafur/gimeracil/oteracil)
• Serplulimab (serplulimab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: The First Affiliated Hospital of Zhengzhou University | Conditions: HER2-positive Gastric Cancer | Phase 2 | Status: NOT_YET_RECRUITING